-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
August 2020
-
Smoking Cessation After Cancer Diagnosis: A Neglected Problem
By Jacek Jassem, MD, PhD, and Carolyn Dresler, MD, MPA Posted: August 21, 2020 The world is currently overwhelmed with cases of the novel virus COVID-19 and its devastating death toll. We acknowledge that finding a treatment, cure, and vaccine is currently our nations’ first responsibility. Amidst this, however, all of our underlying diseases continue…
-
Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. However, approximately 20% to 30% of patients with metastatic NSCLC have an oncogene-driven disease, for which targeted therapies with mutation-specific tyrosine kinase inhibitors (TKIs) are…
-
IASLC Journals Share Exciting Milestones on Metrics Journeys
By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 impact factor of 13.357, an increase from 12.460 in 2018. Th is moves the journal’s rank to 3rd out of 64 respiratory medicine journals and…
-
Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data
By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and those with adenocarcinoma histology, but molecular testing guidelines recommend testing all patients with non-squamous NSCLC for ROS1 rearrangements regardless of smoking history. Crizotinib was the…
-
The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset
Posted: August 21, 2020 The Chen-Huang Center for EGFR Mutant Lung Cancers, founded at Dana-Farber Cancer Institute earlier this year, is poised to make advances in the study and treatment of this subset of lung cancer. Funded through a $5 million gift from Winston Chen, PhD, and his wife Phyllis Huang, the Chen-Huang Center is…
-
Expanding Efforts Help Address Disparities in Lung Cancer Care
By Kara Nyberg, PhD Posted: August 19, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to care. “There are some systemic barriers that make it difficult for people to obtain equitable treatment by race and class in the United States,” regardless…
-
A Roadmap to Improving Lung Cancer Care in the Middle East and North Africa
By Abdul Rahman Jazieh, MD, MPH Posted: August 21, 2020 Countries in the Middle East and North Africa region have significant variation in their socioeconomic status, healthcare resources, infrastructure, and approaches to healthcare provisions. The burden of lung cancer in these countries is huge, and it is only going to increase in the foreseeable future.…
-
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain metastases during the course of their illness.1 Traditionally, the treatment for brain metastases included surgery, whole-brain radiotherapy (WBRT), or stereotactic radiosurgery (SRS). Due to neurocognitive…
-
Managing lung cancer in the time of COVID-19
Register Now REGISTER NOW for the Medscape Education and IASLC Exclusive Webinar: Immunotherapy and the COVID-19 Pandemic: Addressing Clinical Case Challenges in Lung Cancer on Tuesday, August 11, 2020 @ 8:00 am EDT. This webinar will discuss the key issues regarding the use of immunotherapy today, including how and when to start and stop therapy,…
-
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 pandemic in how clinical trials are conducted, as well as the implications of these changes and what can be expected going forward. Q: How has…
View ILCN Archives
Provider Resources
Popular Articles